Clinical Trial: A Study of Roginolisib in Combination with Ruxolitinib in Patients with Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06887803) titled 'A Study of Roginolisib in Combination with Ruxolitinib in Patients with Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors' on Feb. 26.

Brief Summary: The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Myelofibrosis (MF)

Intervention: DRUG: Roginolisib

IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up t...